July 2013 Issue Table Of Contents

From The Editor

• Is Closing Your Manufacturing Plant The Best Option?

Ask The Board

• Ask The Board July 2013

Capitol Perspectives

• Washington’s Baseless Sense Of Complacency On Entitlement Reform

Companies To Watch

• BioDefense And BioTherapeutics Gain Federal Support

Outsourcing Insights

• Prefilled Syringe Technology Benefits Patients, Healthcare Providers, And Drug Makers

Bio Innovation notes

• Demand For Innovation In High-Value Bioprocessing

Feature

• J&J’s Approach To Drug Discovery And Breakthrough Therapy
• Aptalis — The “Three Ms” Of Specialty Pharma

Inside The Industry

• Biosimilars In Emerging Markets
• Generic Drugs: An Impending Drought?
• Perils And Challenges Of Building A Biotech In Kentucky
• Norwegian Biotech Faces The Funding Gap
• Shifting Recruitment Patterns In The Pharma Industry
• New Trends In Pharma/Bio Executive Compensation
• Serialization Approval Possible By August
• GDUFA Sheds New Light On Industry’s Common Ground

Industry Leader

• Reformulating Drugs: The Promise For Novel Therapeutics And New Targets
• The Advent Of Electronic Source Records In Clinical Trials
• The Importance Of Succession Planning